Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 07/02/2019 Ein Porträtfoto des Mediziners.

    Artificial intelligence in ophthalmology

    Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-ophthalmology
  • Prime Vector Technologies GmbH - 09/04/2020

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Press release - 01/12/2022

    Development of the immune system before and after birth

    The newborn's immune system is suddenly confronted with microorganisms, food and numerous environmental influences at birth. How do the baby's immune cells prepare for this moment during pregnancy and birth? How do external influences shape the immune system immediately after birth? And what influence does an event like a premature birth have?

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/development-immune-system-and-after-birth
  • Press release - 10/04/2024

    Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program

    Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-grants-500k-cellnroll-2023-innovation-fellowship-program
  • Press release - 02/03/2026

    Novel therapy for Phelan-McDermid syndrome Drug development to be funded with up to 1.7 million euros

    An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-therapy-phelan-mcdermid-syndrome-drug-development-be-funded-17-million-euros
  • Press release - 23/03/2026

    After a Heart Attack: Inflammation Weakens the Heart’s Energy Production

    Why does heart function often continue to deteriorate after a heart attack, even though blood flow has been restored? A research team from the DZHK sites Heidelberg and North has now identified an important mechanism: an inflammatory switch in cardiomyocytes can impair cellular energy production and thereby drive the development of heart failure. The results were published in Nature Communications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-heart-attack-inflammation-weakens-hearts-energy-production
  • Article - 24/01/2019 The photo shows an ultra filtration system.

    Scientists to combat antibiotic-resistant bacteria in wastewater

    In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.

    https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
  • Press release - 13/07/2021

    Breakthrough in research on age-related macular degenerationtion

    Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-research-age-related-macular-degenerationtion
  • Press release - 10/07/2024

    HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

    HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration
  • Press release - 28/07/2025

    New Max Planck Center with South Korea deepens biomedical research

    Scientists at the Max Planck Institutes for Medical Research in Heidelberg with its new departments based in Heilbronn, and for Neurobiology of Behavior – caesar in Bonn, and at the Institute for Basic Science at Yonsei University in Seoul will pool their expertise in future. The aim of the new Max Planck Center is to visualize cellular processes deep within human tissue and influence them in a targeted manner — without damaging the tissue.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-max-planck-center-south-korea-deepens-biomedical-research
  • Press release - 12/08/2025

    Biomarkers for Brain Insulin Resistance Discovered in the Blood

    If the brain no longer responds properly to insulin (insulin resistance), this can lead to overweight, diabetes, and Alzheimer's disease. Researchers at the DZD in Potsdam and Tübingen have discovered small chemical modifications to genetic material (epigenetic changes*) in the blood that indicate how well the brain responds to insulin. These markers could help to detect insulin resistance in the brain – by means of a simple blood test.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-brain-insulin-resistance-discovered-blood
  • Press release - 20/11/2024

    New bioengineering approaches for the automated production of complex organoids

    The reproducible and precise production of complex organoid models to simulate human organ malfunctions is the focus of an interdisciplinary research project at Heidelberg University. A research team from the life and engineering sciences is looking to combine the engineering of molecular systems with machine learning and automated production methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-ansaetze-des-bio-engineering-fuer-die-automatisierte-herstellung-komplexer-organoide
  • Press release - 12/03/2025

    Hepatic stellate cells control liver function and regeneration

    Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions have hardly been studied to date. Researchers from the German Cancer Research Center, the Mannheim Medical Faculty and Columbia University have now published that hepatic stellate cells control liver metabolism as well as liver regeneration and size. The results of the study could contribute to new therapeutic approaches for liver diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hepatic-stellate-cells-control-liver-function-and-regeneration
  • Press release - 22/09/2025

    Research into novel microelectrodes: Dr. Maximilian Becker receives NanoMatFutur funding

    With the FeMEA project – Ferroelectric Microelectrodes for Biomedical Applications – Hahn-Schickard is setting a pioneering course in bioelectronics research. The aim of the project is to develop novel microelectrode arrays in which ferroelectric materials are used as functional interfaces in CMOS chips for the first time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-novel-microelectrodes-dr-maximilian-becker-receives-nanomatfutur-funding
  • Press release - 20/12/2021

    Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome

    Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
  • Press release - 21/06/2022

    Another step towards synthetic cells

    Scientists from the 2. Physics Institute at the University of Stuttgart and the Max Planck Institute for Medical Research were now able to take the next step towards synthetic cells: They introduced functional DNA-based cytoskeletons into cell-sized compartments and showed functionality. The results were recently published in Nature Chemistry.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/another-step-towards-synthetic-cells
  • Press release - 23/06/2022

    Cancer patients receiving immunotherapy: no evidence of increased risk for severe immune complication after COVID-19 vaccination

    Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A team of Heidelberg physicians and scientists has now shown in a clinical study: Increased serum levels of the characteristic cytokines occur frequently in cancer patients, but clinically relevant cases of the dreaded syndrome were not…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-patients-receiving-immunotherapy-no-evidence-increased-risk-severe-immune-complication-after-covid-19-vaccination
  • Press release - 07/06/2024

    German Research Foundation honors researchers for animal testing alternatives

    Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-research-foundation-honors-researchers-animal-testing-alternatives
  • Press release - 28/04/2022

    Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

    Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
  • Press release - 31/08/2022

    Using nanopores to detect epigenetic changes faster

    Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-nanopores-detect-epigenetic-changes-faster
  • Press release - 08/01/2024

    Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor

    Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv
  • Press release - 28/03/2025

    Quality Assurance in the Cell: Preventing Defective Protein Blueprints

    Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger RNA – a prerequisite for protein synthesis in the cell. The poorly characterized factors are crucial to ensuring that the molecular machine responsible for splicing is working correctly. A research team has deciphered how the two cellular quality inspectors work.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-assurance-cell-preventing-defective-protein-blueprints
  • Press release - 24/06/2024

    Trustworthy AI Made in Mannheim

    How can we use artificial intelligence (AI) to make comprehensible medical decisions? A new project at the University of Mannheim, which has received funding from the Federal Ministry of Education and Research (BMBF), will analyze this question.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/trustworthy-ai-made-mannheim
  • Press release - 07/05/2025

    Contactless. Precise. Pioneering: Muscle Monitoring with Quantum Sensors

    A research team led by PD Dr. Justus Marquet and from the Hertie Institute for Clinical Brain Research has developed two methods that allow muscle activity and training-induced adaptations to be measured completely contactlessly. The studies demonstrate that magnetic fields generated during muscle activity can be captured using highly sensitive quantum sensors - without the need for electrodes or skin contact.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/contactless-precise-pioneering-muscle-monitoring-quantum-sensors

Page 9 / 22

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 22
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search